Clinical Trials

Our most advanced investigational therapy, axicabtagene ciloleucel, has been submitted to the U.S. Food and Drug Administration for the treatment of patients with aggressive non-Hodgkin lymphoma (NHL). Additional indications are being pursued for axicabtagene ciloleucel and the KTE-C19 development program as well as for our TCR pipeline and second generation technology. We expect these indications to cover a variety of blood cancers and solid tumors.

View our clinical trials on ClinicalTrials.gov